Synopsis: A Small-cap Company that provides diagnostic services is in focus today after announcing strong Q2 results.
India’s leading consumer healthcare brand in diagnostic services, is in the spotlight today after posting Q2FY26 results. Read the article below for detailed insights into its performance.
With a market capitalization of Rs. 26,255.24 crore, the shares of Dr Lal Pathlabs Limited is trading at Rs. 3,135, up by 1.48 percent from its previous closing price of Rs. 3,089.40. The stock has touched an intraday high of Rs. 3,208.90 in today’s trading session.
Bonus Issue
Dr Lal Pathlabs Limited has announced a record date for the 1:1 bonus share issue, giving one new fully paid-up equity share of Rs. 10 for each existing share. The company will announce the record date for determining shareholders’ eligibility to receive bonus equity shares at a later time.
Q2FY26 Results & Dividend Announcements
Dr Lal Pathlabs Limited reported Rs. 730.6 crore in revenue for the second quarter of FY26, an 10.66 percent increase over the Rs. 660.2 crore for the same period in FY25. It increased by 9.08 percent as compared to Rs. 669.8 crore in Q1 FY26.
The company’s EBITDA for Q2 FY26 stood at Rs. 224.1 crore, up by 16.54 percent from Rs. 192.3 crore in Q1 FY26, and inclined by 10.66 percent from Rs. 202.5 crore in Q2 FY25.
The consolidated net profit for the second quarter of FY26 was Rs. 152.2 crore, which was 14.35 percent higher than the Rs. 133.1 crore reported in the previous quarter and increased by 17.08 percent from Rs. 130 crore in Q2 FY25. Profit growth was also reflected in earnings per share (EPS), which increased to approximately Rs. 18.05 in Q2 FY26 from Rs. 15.52 in Q2 FY25.
The company has announced an 2nd interim dividend of Rs. 7 per equity share (70 percent of face value of Rs. 10), with November 7, 2025, designated as the record date to determine eligible shareholders.
About the company
Dr. Lal PathLabs is a leading diagnostic service provider in India, offering a wide range of tests for diagnosis, prevention, and treatment through a nationwide network. As of March 31, 2025, it operates 298 laboratories, 6,607 patient service centers, and 12,365 pickup points, serving individuals, hospitals, and corporations.
A return on equity (ROE) of about 24.3 percent, a return on capital employed (ROCE) of about 28.9 percent and debt to equity ratio of 0.07 demonstrate the company’s financial position. At the moment, the company’s P/E ratio is 51x higher as compared to its industry P/E 37.4x.
As of September 2025, the company’s shareholding pattern shows that promoters hold 53.21 percent of the total equity, indicating strong promoter ownership. Foreign Institutional Investors (FIIs) hold 21.86 percent, while Domestic Institutional Investors (DIIs) own 18.22 percent. The government holds 0.27 percent, public shareholding stands at 6.07 percent, and 0.37 percent by others.
Written By Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
